Sponsored by Sica Media*

TODAY’S TOP ALERT! 

Nasdaq: EPRX

Good afternoon!

There are a lot of sad traders out there today after Target’s huge earnings miss sent shares tumbling 20% and the broader markets down with it.

But you’re not sad, right?!

You shouldn’t be if you caught my “tactical trade” idea of the day this morning.

Before the bell, I wrote to you that “when it comes to promising setups, I’ve found one that’s about as good as it gets.”

I was talking about a perfect wedge pattern that had formed on a small-cap pharma stock called Eupraxia Pharmaceuticals (EPRX).

I wrote that “If the stock breaks above the $3.20 level, I think it could be in store for its next major gap up.”

Well it broke the $3.20 level all right, and I’d say this qualifies as a major gap up:

It helped that today, the company unveiled “new pharmacokinetic ("PK") data from its Phase 2a Eosinophilic Esophagitis ("EoE") program.”

Management believes the data “underscore the unique capabilities of Eupraxia's proprietary DiffuSphere™ platform technology, which aims to provide precise, localized, safe, and effective long-lasting drug delivery.”

If you caught my dispatch this on EPRX morning, congratulations! That was a great win to follow, and there’s still plenty of trading left in the day.

Speaking of other trading, I’ve had a fun day getting after it with my Unlimited members! Today, we stalked CALLS on GEV…

As always (especially LATELY!) we were in for some back and forth action 🎢…

I patiently waited for a pullback and jumped in (yes, with my own real money) close to 10AM:

Saw it dip down even further…

What’s happening?

Is this thing gonna fall apart?

On the EDGE of our seats 😬…

But NO, things turned around and then I got one of my FAVORITE questions:

That would be up to YOU, Rich!  But it wasn’t a big enough move for me YET to get too excited about feeding the ducks.  

I’m holding my position and plan to hold overnight after NVDA earnings. Yes, a bit of a gamble, but that’s how I roll (sometimes!).

Let’s keep an eye on this one and see what’s coming down the pike. Those ducks can wait!

To Your Success,

Jeff Bishop

Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull

*Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”

Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received twenty five thousand dollars (cash) from Sica Media for advertising Eupraxia Pharmaceuticals Inc for a one day marketing program on November 20, 2024. This was paid by someone else not connected to Eupraxia Pharmaceuticals Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.

Now, diving right into Eupraxia Pharmaceuticals Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1.ties br0ker-deale.r, br0ker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry auth.ority, or any self-regulat0ry organization.

So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.